IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?

Trimmomatic: a flexible trimmer for Illumina sequence data

Anthony Bolger, Marc Lohse, Björn Usadel · Bioinformatics · 2014 · 69.7K citations · Full text

Life Sciences, Bioinformatics, Molecular Biology +13

Assessment of Minimal Residual Disease in Standard-Risk AML

Adam Ivey, Robert K. Hills, Michael A. Simpson et al. · New England Journal of Medicine · 2016 · 836 citations · Full text

Medicine, Hematology, Molecular Genetics +16

<i>IDH1</i>and<i>IDH2</i>Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With<i>NPM1</i>Mutation Without<i>FLT3</i>Internal Tandem Duplication

Peter Paschka, Richard F. Schlenk, Verena I. Gaidzik et al. · Journal of Clinical Oncology · 2010 · 791 citations

Life Sciences, Genetics, Hematology +16

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

Rob A. Cairns, Mark D. Minden, Edward M. Driggers et al. · The Journal of Experimental Medicine · 2010 · 727 citations · Full text

Life Sciences, Biochemistry, Oncology +17

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations

Katharine Yen, Jeremy Travins, Fang Wang et al. · Cancer Discovery · 2017 · 458 citations · Full text

Medicine, Oncology, Pharmacology +17